Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

The process of regulating for a future outside the EU gets fully underway in the UK parliament

Executive Summary

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.

You may also be interested in...



UK Devices Bill Back On The Agenda As Govt Tries To Get COVID-19 Crisis Under Control

Post-Brexit planning is now fully back on the agenda in the UK, and work to shape its post-EU medtech regulatory future is also restarting.

UK Devices Bill Offers Medtech An EU MDR Alternative – Or Better?

With the obvious distractions of coronavirus, the UK Medicines and Medical Devices bill has entered its second reading in parliament, accompanied by a drive for it to succeed from the government and opposition parties.

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel